70.25↑0.00 (0.00%)
03:48 PM,3rd Oct 202370.00↑-0.79 (-1.12%)
04:00 PM,3rd Oct 2023BSE : 540937
NSE : MEDICO
Sector : Health care
ISIN Code : INE630Y01024
Last Updated: Oct 03 2023 | 04:00 PM IST
Market Cap (₹ Cr) | 583 |
Turnover (₹ Cr) | 0.08 |
Volume (Shares) | 109008 |
Face Value | 2 |
52-WK High | 100.70 |
52-WK High Date | 31 May 2023 |
52-WK Low | 25.80 |
52-WK Low Date | 29 Sep 2022 |
All Time High | 100.70 |
All Time High Date | 31 May 2023 |
All Time Low | 16.52 |
All Time Low Date | 10 Aug 2022 |
Medico Remedies Limited was incorporated as a private limited company with the name Medico Remedies Private Limited on March 18 1994. The status of the Company was changed to a public limited company and the name of the Company was changed to Medico Remedies Limited on March 6 2017. Medico Remedies is a pharmaceutical formulation manufacturing company with manufacturing and marketing capabilities in formulation with focus on anti-infective Beta-Lactums cephalosporins antimalarial antiretroviral anti-ulcer drugs and antacids vitamins haematinics and other supplements. Further in addition to the above the Company also has manufacturing and marketing capabilities in other drugs such as NSAIDS antihistaminic antidiabetics cardio vascular drugs diuretics anti-epileptics combination drug kits syrups and cream & gel for various therapeutic segments.The Company began its operations in the year 1994 with manufacturing and servicing of diuretics anti-malarials NSAIDS tablets anti-reterovirals anti-ulcer drugs and anti-acids tablets. Over the years the company has expanded its scale and scope of operations and currently the Company is engaged in manufacture of formulations for various medicines. As part of this expansion in the year 1999 & 2002 the company has acquired two adjacent plots of 1023.50 sq. metres each respectively for setting up the plant at Palghar Maharashtra. The plant is divided into two units i.e. general formulations unit and betalactam unit; the beta lactam unit is further divided into two segments -penicillin and cephalosporins.The Company has built a strong relationship with its customers for drug formulations. The clients include Indian as well as foreign pharmaceutical companies like Anphar Limited Saad Medical Manfes Pharmaceuticals & Chemical Industries Award Global Company Limited Directorate of Health Services (DHS Maharashtra) to name a few. The Company also earns revenue from the sale of licenses such as FMS license FPS license and MESI license.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 583 |
EPS - TTM (₹) [S] | 0.99 |
P/E Ratio (X) [S] | 13.30 |
Face Value (₹) | 2 |
Latest Dividend (%) | - |
Latest Dividend Date | - |
Dividend Yield (%) | - |
Book Value Share (₹) [S] | 5.28 |
P/B Ratio (₹) [S] | 13.30 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 69.05 71.05 |
Week Low/High | 69.05 73.00 |
Month Low/High | 68.50 80.00 |
Year Low/High | 25.80 101.00 |
All time Low/High | 3.35 101.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | -1.87% | -2.02% | -0.66 | -0.69% |
1 Month | -10.44% | -10.40% | 0.19 | 0.48% |
3 Month | -7.58% | -7.32% | 0.47 | 1.07% |
6 Month | -4.08% | -4.75% | 10.84 | 12.25% |
1 Year | 142.32% | 145.29% | 15.36 | 15.64% |
3 Year | % | % | 69.29 | 71.05% |
Date | Client Name | Exchange | Transaction | Quantity | Price |
---|---|---|---|---|---|
07-09-2023 | AUS ENTERPRISES | NSE | BUY | 700000 | 75.00 |
23-06-2023 | SATHISH SRINIVAS NAYAK | NSE | BUY | 637264 | 64.94 |
23-06-2023 | SATHISH SRINIVAS NAYAK | NSE | SELL | 637264 | 65.16 |
09-06-2023 | VENKATESHWARA INDUSTRIAL PROMOTION CO.LIMITED | NSE | SELL | 550000 | 82.69 |
17-04-2023 | AKSHAYKUMAR RAJENDRABHAI OSWAL | NSE | BUY | 458120 | 83.33 |
17-04-2023 | AKSHAYKUMAR RAJENDRABHAI OSWAL | NSE | SELL | 435686 | 84.04 |
21-03-2023 | AKSHAYKUMAR RAJENDRABHAI OSWAL | NSE | BUY | 484634 | 85.59 |
21-03-2023 | AKSHAYKUMAR RAJENDRABHAI OSWAL | NSE | SELL | 486496 | 85.58 |
28-11-2022 | EMRALD COMMERCIAL LIMITED | NSE | SELL | 100000 | 282.36 |
27-09-2022 | S K GROWTH FUND PVT.LTD. | NSE | SELL | 108000 | 119.60 |
Load More |
Name | Price(In Rs) | Chg(%) | Mkt Cap(Rs Cr) | Sales(Rs Cr) | Profit(Rs Cr) | EPS(Rs) | P/E(x) |
---|
Category | Share(%) |
---|---|
Promoter | 73.34 |
Financial Institutions Banks | 0.00 |
Foreign Institutional Investors | 1.20 |
Insurance Companies | 0.00 |
Mutual Funds Uti | 0.00 |
Other Institutional Investors | 0.00 |
Indian Public | 13.51 |
Others Non Institutional Investors | 11.96 |
Custodians | 0.00 |
Announcement Date | Purpose | From | To | Remarks |
---|---|---|---|---|
Data Not Found |
Search for Price History
Date | Open | High | Low | Close | Shares | Trades |
---|---|---|---|---|---|---|
Data Not Found |
Load more
Independent Director : Deepak Vekaria
Registered Office: 1105/1106 11-Flr Hubtown Solar, N S Phadke Marg Andheri East,Mumbai,Maharashtra-400069 Ph: 91-22-2670 1055/66
Email:info@medicoremedies.com